MAAT INDEX

CLAIM #48381 · Pfizer Inc (PFE) · 2024Q1 earnings call · May 1, 2024 · due Dec 31, 2026

I would just say that the focus that we have around improving our cost of goods sold is a multiyear journey. And these costs that we are working to improve take time to adjust and to further implement ways to be more effective and efficient in this infrastructure.

David Denton · CFO

PENDING
graded after results covering Dec 31, 2026 are reported

How to check this claim

Look at: Cost of goods sold as % of revenue (gross margin), annual

It came true if: Gross margin percentage improves (higher) in FY2025 and FY2026 versus FY2024 reported figure

Where: Company income statement (10-K / annual earnings release)

In context

commendation. Operator: We'll take our next question from Mohit Bansal with Wells Fargo. Mohit Bansal: Maybe a question for Dave. Just wanted to understand the cadence of margin improvement as you are embarking on the cost management journey throughout the year because I mean, you had a really high EPS because of the onetime item, but if you think about margin profile over the year, how should we think about it? I understand fourth quarter could be impacted with COMIRNATY revenues. And then when we get into 2025, should we think about better leverage or do you think there could be more opportunity to [indiscernible] expenses in '25 as well? David Denton: Yes, thank you for the question. I would say that without giving -- since we don't guide to quarterly expectations for gross margin, I would just say that the focus that we have around improving our cost of goods sold is a multiyear journey. And these costs that we are working to improve take time to adjust and to further implement ways to be more effective and efficient in this infrastructure. So I wouldn't think of that having a significant impact on 2024 but more -- if it would, it would be late 2024 but more '25 and '26. But more to come. As we know more and as we develop our plans more specifically, we'll be certain to share some specifics around that. P Albert Bourla: Thank you. Operator: We'll take our next question from Chris Schott with JPMorgan. Christopher Schott: Just 2 ones for me here. Just on Abrysvo, just really quickly following up on the earlier commentary. Can you just update us on where we are in terms of contracting efforts and progress in the retail channel, just addressing some of the market share issues you highlighted last year? I guess my specific question is, do you have line of sight on contracting at this point? Or is that still something that's

Verify independently

SEC filings for PFE · Claim quote is verbatim from the 2024Q1 earnings call.